Tirzepatide is a linear polypeptide made up of 39 amino acids that was developed to fight type 2 diabetes. Tirzepatide is a peptide that has the potential to act as an agonist at both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. GLP-1 (which is in the upper gut) and GIP (which is in the lower gut). The duo work together to stimulate insulin secretion after a meal is eaten,

Both GLP-1 and GIP are released after food intake and stimulate insulin secretion. Tirzepatide works by mimicking both these receptor agonists, in turn, signalling the pancreas to stop releasing insulin after food intake and alerting the liver to decrease glucose levels.

These processes slow down digestion, improve glycemic control and help people feel fuller for longer after eating meals which can all lead to body weight reduction and weight control.

Research suggests that Tirzepatide may modify adiponectin levels, with low levels of adiponectin linked to atherosclerosis, obesity, and heart issues. In contrast, higher levels have been associated with a decreased risk of these ailments. Studies on individuals with type 2 diabetes have indicated that Tirzepatide may enhance lipoprotein biomarkers, leading to lower levels of triglycerides, apoC-III, and other lipoproteins, thereby reducing the risk of heart issues. Moreover, the peptide appears to decrease scavenger receptors in macrophages, increase cholesterol efflux, and boost adiponectin levels, increasing HDL levels while reducing triglyceride levels, all of which are linked to a lower risk of heart issues.